OncoSec Medical (NASDAQ:ONCS – Get Rating) released its earnings results on Tuesday. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02, Fidelity Earnings reports.
Shares of ONCS stock opened at $0.80 on Wednesday. The stock has a market cap of $31.57 million, a PE ratio of -0.77 and a beta of 2.03. The business has a 50-day simple moving average of $0.87 and a 200-day simple moving average of $0.97. OncoSec Medical has a 52-week low of $0.67 and a 52-week high of $4.25.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ONCS. Susquehanna International Group LLP raised its holdings in OncoSec Medical by 62.7% in the 4th quarter. Susquehanna International Group LLP now owns 44,075 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 16,990 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of OncoSec Medical in the third quarter valued at approximately $53,000. Bank of New York Mellon Corp purchased a new position in OncoSec Medical in the third quarter worth approximately $109,000. Renaissance Technologies LLC grew its position in OncoSec Medical by 140.0% in the fourth quarter. Renaissance Technologies LLC now owns 249,361 shares of the biotechnology company’s stock worth $239,000 after acquiring an additional 145,463 shares during the period. Finally, Geode Capital Management LLC lifted its stake in OncoSec Medical by 7.1% during the fourth quarter. Geode Capital Management LLC now owns 262,478 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 17,467 shares in the last quarter. 13.98% of the stock is owned by institutional investors.
About OncoSec Medical (Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Under-The-Radar RF Industries Is A Steal At These Prices
- Procter & Gamble Stock Continues to Be Resilient Despite Turmoil
- Analog Devices Stock is a Defensive Semiconductor Play
- HP Inc. Stock Is a Steady Eddie Gainer
- Insiders Sell Tractor Supply Company, Oh No!
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.